Arvinas
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
CEOJohn G. Houston
CEOJohn G. Houston
Employees445
Employees445
HeadquartersNew Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded2013
Founded2013
Employees445
Employees445
ARVN Key Statistics
Market cap2.21B
Market cap2.21B
Price-Earnings ratio-4.98
Price-Earnings ratio-4.98
Dividend yield—
Dividend yield—
Average volume687.71K
Average volume687.71K
High today$32.72
High today$32.72
Low today$31.04
Low today$31.04
Open price$31.73
Open price$31.73
Volume778.70K
Volume778.70K
52 Week high$53.08
52 Week high$53.08
52 Week low$13.57
52 Week low$13.57
ARVN News
Yahoo Finance 2d
Arvinas, Inc. Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo FinanceArvinas, Inc. (ARVN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. T...
Analyst ratings
90%
of 20 ratingsBuy
90%
Hold
10%
Sell
0%